Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1278 participants.

Also called NCT03596450

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,278 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03596450
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03596450. Randomized; no masking; primary purpose treatment. Start 2018-07-13 (actual); primary completion 2022-06-09 (actual). Results posted on 2023-08-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Standard of care
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03596450
Content hash
72bc57aece213cc9e87130da6f8b0a6552bd2b057e70559be4d993b3e2ad706b